Evidence map›Paper›PMID 27018893›Full record

ArticlePloS one2016

Reduction in Malaria Incidence following Indoor Residual Spraying with Actellic 300 CS in a Setting with Pyrethroid Resistance: Mutasa District, Zimbabwe.

Mufaro Kanyangarara, Edmore Mamini, Sungano Mharakurwa, Shungu Munyati, Lovemore Gwanzura, Tamaki Kobayashi, Timothy Shields, Luke C Mullany, Susan Mutambu, Peter R Mason and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Mufaro KanyangararaDepartment of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Edmore MaminiBiomedical Research Training Institute, Harare, Zimbabwe.
Sungano MharakurwaBiomedical Research Training Institute, Harare, Zimbabwe.
Shungu MunyatiBiomedical Research Training Institute, Harare, Zimbabwe.
Lovemore GwanzuraBiomedical Research Training Institute, Harare, Zimbabwe.
Tamaki KobayashiDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Timothy ShieldsDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Luke C MullanyDepartment of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Susan MutambuNational Institute of Health Research, Harare, Zimbabwe.
Peter R MasonBiomedical Research Training Institute, Harare, Zimbabwe.
Frank C CurrieroDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
William J MossDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Southern Africa International Centers of Excellence for Malaria Research
Johns Hopkins University · USBiomedical Research and Training Institute · ZWUniversity of Zimbabwe · ZW

Funding

TransmissionU19AI089680 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WILLIAM J MOSS · 2010 to 2026
$25.6M
NIAID NIH HHS U19 AI089680
6 · The paper itself

Abstract

backgroundMore than half of malaria cases in Zimbabwe are concentrated in Manicaland Province, where seasonal malaria epidemics occur despite intensified control strategies. Recently, high levels of pyrethroid and carbamate resistance were detected in Anopheles funestus, the major malaria vector in eastern Zimbabwe. In response, a single round of indoor residual spraying (IRS) using pirimiphos-methyl (an organophosphate) was implemented in four high burden districts of Manicaland Province from November 1, 2014 to December 19, 2014. The objective of this study was to evaluate the effect of this programmatic switch in insecticides on malaria morbidity reported from health care facilities in Mutasa District, one of the worst affected districts in Manicaland Province.

methodsThe number of weekly malaria cases for each health facility 24 months prior to the 2014 IRS campaign and in the subsequent high transmission season were obtained from passive case surveillance. Environmental variables were extracted from remote-sensing data sources and linked to each health care facility. Negative binomial regression was used to model the weekly number of malaria cases, adjusted for seasonality and environmental variables.

resultsFrom December 2012 to May 2015, 124,206 malaria cases were reported from 42 health care facilities in Mutasa District. Based on a higher burden of malaria, 20 out of 31 municipal wards were sprayed in the district. Overall, 87.3% of target structures were sprayed and 92.1% of the target population protected. During the 6 months after the 2014 IRS campaign, a period when transmission would have otherwise peaked, the incidence of malaria was 38% lower than the preceding 24 months at health facilities in the sprayed wards.

conclusionsPirimiphos-methyl had a measurable impact on malaria incidence and is an effective insecticide for the control of An. funestus in eastern Zimbabwe.

Indexed as

AnimalsAnophelesHumansIncidenceInsecticide ResistanceInsecticidesMalariaMosquito ControlOrganothiophosphorus CompoundsZimbabweInsecticidesOrganothiophosphorus Compoundspirimiphos methyl

Identifiers

PMID27018893
PMCPMC4809594
OpenAlexW2319704006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.